Deepen — Understanding Satiety & GLP-1
Deepen your understanding of satiety and GLP-1
Three deep-dive resources to explore the integrative physiology of satiety — hormonal, mechanical, and perceptual pathways — and the rationale of mechanosensorial adjuncts alongside GLP-1 therapies.
Satiety is one of the most discussed — and one of the least understood — concepts in current obesity care. The rapid rise of GLP-1 therapies has put hormonal modulation of appetite at the center of the conversation. But satiety is, by nature, an integrative phenomenon: it results from the convergence of hormonal, mechanical, cognitive, and emotional signals at the level of central nervous system circuits involved in food intake regulation.
This page brings together three deep-dive resources to help readers explore each of these dimensions — and how they may articulate with the mechanosensorial rationale of GASTER control®. Each resource stands on its own; together, they form a coherent reading path for those who want to go beyond surface-level explanations.
How to navigate these resources
Depending on your background, different entry points may be more useful:
Satiety is not a single signal — it's an integrated network
For decades, satiety was treated as a vague subjective sensation, addressed indirectly through portion control or behavioral counseling. Research over the past twenty years has revealed a more complex picture: satiety is the result of multiple physiological pathways interacting in parallel, each contributing distinct information to the brain's appetite-regulating circuits.
Three pathways are particularly well-characterized in the literature:
The hormonal pathway — mediated by gut peptides such as GLP-1, PYY, CCK, ghrelin, and others — sends biochemical signals about nutrient intake and energy status to the hypothalamus and brainstem. This is the pathway targeted by current GLP-1 receptor agonists.
The mechanosensorial pathway — mediated by stretch receptors in the gastric wall and surrounding tissues — sends information about volume, distension, and physical fullness via vagal afferents. This is the pathway primarily affected by bariatric surgery, and the one explored by external mechanical adjuncts such as GASTER control®.
The cognitive and emotional pathway — mediated by higher cortical and limbic circuits — integrates context, expectation, memory, emotion, and social cues into the eating experience. This is the pathway addressed by behavioral therapy, mindful eating practices, and structured psychological support.
This integrative view is consistent with the position adopted by the European Association for the Study of Obesity (EASO), whose 2025 framework published in Nature Medicine emphasizes personalized, multidimensional approaches to obesity care — moving beyond BMI to consider body composition, metabolic profile, and physiological pathways simultaneously. EASO explicitly recommends pharmacological treatments such as GLP-1 receptor agonists alongside lifestyle interventions and complementary approaches, reflecting the same logic of articulated pathways described above.
Three resources to explore
Each of the three pages below explores one facet of this integrated picture. They can be read in any order — but for those new to the topic, we suggest the sequence below.
What is Satiety
The integrated physiology of fullness — what triggers it, how the brain interprets it, and why willpower is rarely the limiting factor in appetite regulation.
ExploreGLP-1 and Satiety
The hormonal pathway in detail: how GLP-1 receptor agonists modulate appetite, what they achieve clinically, and what remains outside their reach when treatment is interrupted.
ExploreGASTER control® & GLP-1
How mechanosensorial signaling complements pharmacological approaches — the rationale of external abdominal compression alongside GLP-1 therapies, during treatment and after.
ExploreLooking for the bigger picture?
Our pillar page maps how these pathways come together in real clinical situations — active GLP-1 treatment, transition, discontinuation, and access constraints.
GLP-1 hub: 4 clinical situationsGASTER control® is not an alternative to GLP-1 therapies or to bariatric surgery. It is approached as a complementary mechanosensorial adjunct within integrated care pathways. The level of clinical evidence currently available remains preliminary; the ongoing observational registry GC-REG-01 aims to expand it.